Protagonist Therapeutics, Inc
PTGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001377121
In the last 90 days, Protagonist Therapeutics, Inc insiders filed 0 open-market purchases and 2 sales; 346 institutions reported holding it in 13F filings for Q2 2026, worth $9.30B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q2 2024
Institutional positions in Protagonist Therapeutics, Inc as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 188
- +4 vs. Q1 2024
- Shares held
- 59.1M
- −844.0K (−1.4%) vs. Q1 2024
- Total value
- $2.05B
- +$313.9M (+18.1%) vs. Q1 2024
- New holders
- 30
- 63 more added
- Sold out
- 26
- 68 more reduced
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTGX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 346 | $9.30B |
| Q1 2026 | 322 | $8.31B |
| Q4 2025 | 319 | $6.18B |
| Q3 2025 | 275 | $4.70B |
| Q2 2025 | 274 | $3.92B |
| Q1 2025 | 275 | $3.15B |
| Q4 2024 | 241 | $2.44B |
| Q3 2024 | 240 | $2.78B |
| Q2 2024 | 188 | $2.05B |
| Q1 2024 | 185 | $1.73B |
| Q4 2023 | 157 | $1.32B |
| Q3 2023 | 144 | $945.9M |
| Q2 2023 | 167 | $1.57B |
| Q1 2023 | 138 | $1.22B |
| Q4 2022 | 137 | $533.3M |
| Q3 2022 | 133 | $398.9M |
| Q2 2022 | 131 | $422.1M |
| Q1 2022 | 140 | $1.19B |
| Q4 2021 | 149 | $1.68B |
| Q3 2021 | 132 | $820.8M |
| Q2 2021 | 139 | $2.16B |
| Q1 2021 | 127 | $1.15B |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Protagonist Therapeutics, Inc; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −25,446−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −22,510−100.0% | Sold out |
| Caxton Associates LP | 0 | $0 | 0.00% | −16,047−100.0% | Sold out |
| Campbell & CO Investment Adviser LLC | 0 | $0 | 0.00% | −13,763−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −11,819−100.0% | Sold out |
| E Fund Management Co., Ltd. | 0 | $0 | 0.00% | −11,304−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −3,037−100.0% | Sold out |
| nVerses Capital, LLC | 0 | $0 | 0.00% | −2,900−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −2,300−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −2,250−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −352−100.0% | Sold out |
| Truvestments Capital LLC | 0 | $0 | 0.00% | −131−100.0% | Sold out |
| Sofos Investments, Inc. | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Credit Suisse AG | – | – | – | – | Not filed |